Drew Messick

Chief Financial Officer

Finance professional with over 20 years of experience driving growth through the successful implementation of financial and operational strategies. Most recently served as the Chief Financial Officer of two privately held life science and technology companies. Drew holds a master’s degree in accounting and is a Chartered Financial Analyst and CPA.

Back to our Team

Get in touch with us to discuss IBC services for your clinical trials.

Mission Statement

Our mission and expertise at Clinical Biosafety Services is to provide accelerated, compliant review of gene transfer/gene therapy clinical trials to a convened review of a site-specific Institutional Biosafety Committee (IBC). We do this by understanding the challenges in the two client relationship of serving an institution and a sponsor.

Our focus is to accelerate the trial, and remove regulatory burden and uncertainty by having our highly trained experts provide friendly, knowledgeable support during the review process. We understand these therapeutics will change medicine, and our service is to bring the trial to enrollment fruition, quickly and compliantly.